A Phase 1 interventional study of SGN-35 in Lymphoma, Non-Hodgkin, Disease, Hodgkin and Lymphoma, Large-Cell, Anaplastic, sponsored by Seagen Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 10th largest by enrollment, is the only one that started in 2006, is one of 6 in phase 1, and was the 1st registered.
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
Browse Lymphoma, Large-Cell, Anaplastic studies →1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 1–39
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Median enrollment 44 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer: none open now, 1 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2006, is one of 8 in phase 1, and was the 2nd registered.
Pfizer’s Lymphoma, Large-Cell, Anaplastic studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Lymphoma, Large-Cell, Anaplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
This study's enrollment of 45 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Browse Lymphoma, Large-Cell, Anaplastic studies →Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Compared within Lymphoma, Large-Cell, Anaplastic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SGN-35
Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
Also known as: brentuximab vedotin
Incidence of adverse events and laboratory abnormalities
Time frame: 1 month after last dose
PK profile
Time frame: 2 months after last dose
Immunogenicity (anti-SGN-35 antibodies)
Time frame: 1 month after last dose
Anti-tumor activity
Time frame: 1 month after last dose
The record gives a start of Nov 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large-Cell, Anaplastic →